253 results match your criteria: "Influenza Research Institute[Affiliation]"

Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV.

BMC Microbiol

January 2024

Division of Infectious Diseases, Advanced Clinical Research Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan.

Background: People living with HIV (PLWH) with chronic inflammation may have an increasing risk for coronavirus disease 2019 (COVID-19) severity; however, the impact of their gut microbiota on COVID-19 is not fully elucidated. Here, we analyzed the temporal changes in the gut microbiota composition of hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected PLWH (PLWH-CoV) and their correlation with COVID-19 severity.

Result: The 16S rRNA analysis results using stool samples (along the timeline from disease onset) from 12 hospitalized PLWH-CoV, whose median CD4 + T cell count was 671 cells/µl, were compared to those of 19 healthy people and 25 PLWH.

View Article and Find Full Text PDF

Here, we assessed the efficacy of a lipid nanoparticle-based mRNA vaccine candidate encoding the receptor-binding domain (LNP-mRNA-RBD) in mice. Mice immunized with LNP-mRNA-RBD based on the ancestral strain (ancestral-type LNP-mRNA-RBD) showed similar cellular responses against the ancestral strain and BA.5, but their neutralizing activity against BA.

View Article and Find Full Text PDF

Cardiovascular disease is one of many risk factors that have been linked to increased severity or mortality in coronavirus disease 2019 (COVID-19) patients; however, the exact role of SARS-CoV-2 in the pathogenesis of cardiac inflammatory injury has not been established. A previous study reported that SARS-CoV-2 causes more severe disease with cardiomyopathy in a J2N-k animal model. Here, we investigated the sensitivity of J2N-k hamsters, as a cardiomyopathy animal model, to a delta strain of SARS-CoV-2 compared to J2N-n control animals.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates rotavirus infections in fully vaccinated children in Zambia, highlighting the emergence of genetically altered viruses that can evade immunity from existing vaccines.
  • Researchers conducted whole genome sequencing on diarrheal stool samples and identified several RVA strains, including mono and multiple reassortant strains, which exhibited differences in antigenic epitope compared to the common vaccine strain, Rotarix.
  • Results suggest that these genetic variations may help the virus escape neutralizing antibodies, indicating a need for improved vaccination strategies and the development of more effective universal rotavirus vaccines.
View Article and Find Full Text PDF

Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.

Cell Rep

December 2023

Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA; Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Tokyo 108-8639, Japan. Electronic address:

Article Synopsis
  • EG.5.1 is a new subvariant of the Omicron XBB variant of SARS-CoV-2 that is becoming more common globally, but its pathogenicity and immune evasion are still not well understood.
  • Research shows that EG.5.1 has similar growth ability and pathogenicity as XBB.1.5 in hamsters, but it spreads more effectively than the older BA.2 variant.
  • Additionally, plasma from recovered patients shows less neutralizing activity against EG.5.1 compared to XBB.1.5, suggesting that these differences might be contributing to its rise in prevalence among humans.
View Article and Find Full Text PDF

Host RNA binding proteins recognize viral RNA and play key roles in virus replication and antiviral mechanisms. SARS-CoV-2 generates a series of tiered subgenomic RNAs (sgRNAs), each encoding distinct viral protein(s) that regulate different aspects of viral replication. Here, for the first time, we demonstrate the successful isolation of SARS-CoV-2 genomic RNA and three distinct sgRNAs (N, S, and ORF8) from a single population of infected cells and characterize their protein interactomes.

View Article and Find Full Text PDF

The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.

View Article and Find Full Text PDF

Characterization of highly pathogenic clade 2.3.4.4b H5N1 mink influenza viruses.

EBioMedicine

November 2023

Department of Pathobiological Sciences, Influenza Research Institute, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, International Research Center for Infectious Diseases, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; Research Center for Global Viral Diseases, National Center for Global Health and Medicine, Tokyo 162-8655, Japan; The University of Tokyo, Pandemic Preparedness, Infection and Advanced Research (UTOPIA) Center, Tokyo 108-8639, Japan. Electronic address:

View Article and Find Full Text PDF

The antigenic evolution of SARS-CoV-2 requires ongoing monitoring to judge the immune escape of newly arising variants. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal sera. We compared 18 datasets generated using human, hamster, and mouse sera, and six different neutralization assays.

View Article and Find Full Text PDF
Article Synopsis
  • - The study analyzed how different variants of SARS-CoV-2 affect immunity, focusing on 21 variants and how they interact with immune responses from people previously infected or vaccinated.
  • - Researchers used a technique called antigenic cartography to identify significant differences in the spike protein of pre-Omicron variants, noting key positions that show variability related to immunity.
  • - They observed that immunity increases notably 4 weeks to over 3 months after the second vaccine dose, and that the initial variant exposure impacts which parts of the spike protein the immune system focuses on, highlighting considerations for future vaccine strategies.
View Article and Find Full Text PDF

Evolution of human H3N2 influenza viruses driven by immune selection has narrowed the receptor specificity of the hemagglutinin (HA) to a restricted subset of human-type (Neu5Acα2-6 Gal) glycan receptors that have extended poly-LacNAc (Galβ1-4GlcNAc) repeats. This altered specificity has presented challenges for hemagglutination assays, growth in laboratory hosts, and vaccine production in eggs. To assess the impact of extended glycan receptors on virus binding, infection, and growth, we have engineered N-glycan extended (NExt) cell lines by overexpressing β3-Ν-acetylglucosaminyltransferase 2 in MDCK, SIAT, and hCK cell lines.

View Article and Find Full Text PDF

The pathogenic and cross-species transmission potential of SARS-CoV-2-related coronaviruses (CoVs) remain poorly characterized. Here we recovered a wild-type pangolin (Pg) CoV GD strain including derivatives encoding reporter genes using reverse genetics. In primary human cells, PgCoV replicated efficiently but with reduced fitness and showed less efficient transmission via airborne route compared with SARS-CoV-2 in hamsters.

View Article and Find Full Text PDF

Recombinant spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2.

Vaccine

September 2023

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan; Pandemic Preparedness, Infection and Advanced Research Center, The University of Tokyo, Tokyo 162-8655, Japan. Electronic address:

The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a glycoprotein, expressed on the virion surface, that mediates infection of host cells by directly interacting with host receptors. As such, it is a reasonable target to neutralize the infectivity of the virus. Here we found that a recombinant S protein vaccine adjuvanted with Alhydrogel or the QS-21-like adjuvant Quil-A effectively induced anti-S receptor binding domain (RBD) serum IgG and neutralizing antibody titers in the Syrian hamster model, resulting in significantly low SARS-CoV-2 replication in respiratory organs and reduced body weight loss upon virus challenge.

View Article and Find Full Text PDF

Development of an Enhanced High-Yield Influenza Vaccine Backbone in Embryonated Chicken Eggs.

Vaccines (Basel)

August 2023

Department of Pathobiological Sciences, School of Veterinary Medicine, Influenza Research Institute, University of Wisconsin-Madison, Madison, WI 53711, USA.

Vaccination is an efficient approach to preventing influenza virus infections. Recently, we developed influenza A and B virus vaccine backbones that increased the yield of several vaccine viruses in Madin-Darby canine kidney (MDCK) and African green monkey kidney (Vero) cells. These vaccine backbones also increased viral replication in embryonated chicken eggs, which are the most frequently used platform for influenza vaccine manufacturing.

View Article and Find Full Text PDF
Article Synopsis
  • In April 2023, the International Committee on Taxonomy of Viruses (ICTV) approved changes to the phylum's classification during their annual vote.
  • The update included the addition of one new family, 14 new genera, and 140 new species.
  • Additionally, the taxonomy featured the renaming of two genera and 538 species, along with the removal of one species and the abolition of four others.
View Article and Find Full Text PDF

Ebola Virus Infection Induces HCAR2 Expression Leading to Cell Death.

J Infect Dis

November 2023

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Ebola virus (EBOV) induces cell death not only in infected permissive cells but also in nonpermissive, bystander cells by employing different mechanisms. Hydroxycarboxylic acid receptor 2 (HCAR2) has been reported to be involved in apoptotic cell death. We previously reported an increase in the expression of HCAR2-specific mRNA in EBOV-infected individuals with fatal outcomes.

View Article and Find Full Text PDF

An Antiviral Role for TRIM14 in Ebola Virus Infection.

J Infect Dis

November 2023

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Article Synopsis
  • Ebola virus (EBOV) has 7 structural proteins and interacts with various host factors, including TRIM14, which enhances immune responses.
  • TRIM14 boosts the activation of interferon-β and nuclear factor-κB, helping to limit virus replication.
  • Mice lacking TRIM14 showed increased susceptibility to EBOV, indicating its role as a protective factor against the virus.
View Article and Find Full Text PDF

Continued Circulation of Highly Pathogenic H5 Influenza Viruses in Vietnamese Live Bird Markets in 2018-2021.

Viruses

July 2023

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA.

We isolated 77 highly pathogenic avian influenza viruses during routine surveillance in live poultry markets in northern provinces of Vietnam from 2018 to 2021. These viruses are of the H5N6 subtype and belong to HA clades 2.3.

View Article and Find Full Text PDF

Vaccination is the most effective countermeasure to reduce the severity of influenza. Current seasonal influenza vaccines mainly elicit humoral immunity targeting hemagglutinin (HA). In particular, the amino acid residues around the receptor-binding site in the HA head domain are predominantly targeted by humoral immunity as "immunodominant" epitopes.

View Article and Find Full Text PDF

The 2002 SARS outbreak, the 2019 emergence of COVID-19, and the continuing evolution of immune-evading SARS-CoV-2 variants together highlight the need for a broadly protective vaccine against ACE2-utilizing sarbecoviruses. While updated variant-matched formulations such as Pfizer-BioNTech's bivalent vaccine are a step in the right direction, protection needs to extend beyond SARS-CoV-2 and its variants to include SARS-like viruses. Here, we introduce bivalent and trivalent vaccine formulations using our spike protein nanoparticle platform that completely protected hamsters against BA.

View Article and Find Full Text PDF
Article Synopsis
  • * In laboratory conditions, Delta and Omicron were exposed to RdRP and 3CLpro inhibitors, revealing that Delta variants mutated to resist 3CLpro inhibitors after five passages, while all variants quickly vanished under RdRP inhibitors.
  • * Results indicate that SARS-CoV-2 is less likely to develop resistance to RdRP inhibitors than to 3CLpro inhibitors, and Delta variants are more prone to acquire resistance compared to Omicron.
View Article and Find Full Text PDF

SARS-CoV-2 has gradually acquired amino acid substitutions in its S protein that reduce the potency of neutralizing antibodies, leading to decreased vaccine efficacy. Here, we attempted to obtain mutant viruses by passaging SARS-CoV-2 in the presence of plasma samples from convalescent patients or vaccinees to determine which amino acid substitutions affect the antigenicity of SARS-CoV-2. Several amino acid substitutions in the S2 region, as well as the N-terminal domain (NTD) and receptor-binding domain (RBD), affected the neutralization potency of plasma samples collected from vaccinees, indicating that amino acid substitutions in the S2 region as well as those in the NTD and RBD affect neutralization by vaccine-induced antibodies.

View Article and Find Full Text PDF

Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination.

Virol J

July 2023

Division of Infectious Diseases, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, 108-8639, Tokyo, Japan.

Background: The mucosa serves as the first defence against pathogens and facilitates the surveillance and elimination of symbiotic bacteria by mucosal immunity. Recently, the mRNA vaccine against SARS-CoV-2 has been demonstrated to induce secretory antibodies in the oral and nasal cavities in addition to a systemic immune response. However, the mechanism of induced immune stimulation effect on mucosal immunity and commensal bacteria profile remains unclear.

View Article and Find Full Text PDF
Article Synopsis
  • Ebola virus (EBOV) is extremely dangerous, with high fatality rates, and while some viral proteins are known to impact its virulence, the exact role of the mucin-like domain (MLD) in disease is less understood.
  • Researchers created a version of EBOV without the MLD to study its effects on disease progression in ferrets, comparing it with the wild-type (WT) virus.
  • The study found no significant differences in growth, time to death, or clinical symptoms between the MLD-lacking virus and the WT virus, suggesting that the MLD is not crucial for the acute pathogenesis of Ebola virus disease (EVD) in ferrets.
View Article and Find Full Text PDF

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters.

EBioMedicine

July 2023

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53711, USA; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo 162-8655, Japan; Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), University of Tokyo, Tokyo 162-8655, Japan. Electronic address:

Background: Like its predecessors in the XBB family, XBB.1.5 is highly immune evasive from therapeutic monoclonal antibodies and neutralizing antibodies generated by vaccination and/or infection.

View Article and Find Full Text PDF